Clinical Studies for Children with Solid Tumors
Studies in patients with solid tumors are available for patients with
both newly diagnosed and recurrent sarcomas. Front-line treatment regimens
are available for patients with previously untreated Ewing's sarcoma of
bone and soft tissue, PNET, rhabdomyosarcoma, and unresectable or metastatic
high-grade non-rhabdomyosarcoma soft tissue sarcomas. Because standard
therapy offers the potential for cure in a large percentage of patients
with non-metastatic sarcomas, new therapeutic modalities have focused
upon treatment for patients with metastatic and recurrent sarcomas. Current
protocols for patients with newly diagnosed sarcomas utilize dose intensive
chemotherapy for patients with non-metastatic sarcomas and offer a combination
of dose intensive chemotherapy and tumor vaccine with T cell transplantation
and interleukin-2 for eligible patients with metastatic sarcomas. Treatment
regimens for patients with recurrent tumors include: an immunotherapy
trial which incorporates a tumor vaccine with interleukin-2 in patients
with recurrent rhabdomyosarcoma and Ewing's sarcoma family of tumors,
a combination of growth factor inhibitors (Sandostatin-LAR +/-Tamoxifen)
designed to reduce circulating levels of insulin-like growth factor type
I (IGF-I) in patients with osteosarcoma.
See also:
Solid Tumor Protocols
Phase I Clinical Trials
Last Updated: March
10, 2003
NCI
Home Page|| NIH Home Page
© 2002-2003, Pediatric Oncology Branch, Center for Cancer Research,
National Cancer Institute
|